Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
- 1Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
Abstract
Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.
Related
- Controlled human infection with Plasmodium falciparum-infected mosquito bites elicits antibodies against mosquito salivary protein SG1L3
- Targeting the Cav1.2-KCa1.1 axis prevents rabies virus internalization and protects against lethal infection
- A commensal-derived sugar protects against obesity by regulating immunometabolism
- CST-Polα/primase, backed up by Rif1, protects telomeric ss-dsDNA junctions from damage recognition and resection
- B Cell Deficiency Protects Against the Development of c‐MET and Beta‐Catenin Driven Hepatocellular Carcinoma in Mice
BibTeX
@article{arroyo2026spike,
title = {{Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection}},
author = {Kayla R. Arroyo and Shengnan Qian and Hansam Cho and Xiaoqing Guan and Qian Liu and Parisa Darvishi and Lanying Du},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272210225},
url = {https://www.mdpi.com/1422-0067/27/22/10225},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
AU - Kayla R. Arroyo
AU - Shengnan Qian
AU - Hansam Cho
AU - Xiaoqing Guan
AU - Qian Liu
AU - Parisa Darvishi
AU - Lanying Du
PY - 2026
DA - 2026/11/15
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272210225
UR - https://www.mdpi.com/1422-0067/27/22/10225
AB - Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.
SN - 1422-0067
ER -